SI-BONE, Inc. filings document formal disclosures for a Nasdaq-listed medical device company developing surgical technologies for compromised bone and sacropelvic disorders. Recent Form 8-K reports furnish quarterly results, preliminary revenue and cash information, Regulation FD presentation materials, and material agreements such as facility lease arrangements.
The company’s proxy materials cover annual meeting matters, board composition, executive compensation, equity awards, and pay-versus-performance disclosure. Additional 8-K disclosures record governance and leadership changes, including board resignations, committee updates, officer transitions, and related compensatory arrangements.
SI-BONE, Inc. reported strong first quarter 2026 results and raised its full-year 2026 outlook. Worldwide revenue grew 11.2% to $52.6 million, with U.S. revenue up 10.0% to $49.3 million and international revenue up 33.9% to $3.3 million.
Gross margin remained high at 79.8%, while net loss narrowed to $4.3 million or $0.10 per share, a 33.8% improvement from the prior year period. Adjusted EBITDA turned meaningfully higher to $2.5 million from $0.5 million, and cash and equivalents were $144.7 million as of March 31, 2026.
Management increased 2026 worldwide revenue guidance to $230–$233 million, implying approximately 14–16% growth, and raised the full-year gross margin expectation to about 79%, while reaffirming expectations for positive adjusted EBITDA.
SI-BONE, Inc. ownership update: First Light Asset Management, LLC and Mathew P. Arens jointly filed an Amendment No. 1 to Schedule 13G reporting beneficial ownership positions. The Manager reports 7,971,486 shares (18.02%) and Mr. Arens reports 8,120,986 shares (18.36%).
The filing explains the Manager acts as investment adviser to separate accounts and private funds and that Mr. Arens controls the Manager and also holds direct shares (23,000 sole; 126,500 joint). Signatures are provided by the Manager's CCO and Mr. Arens.
SI-BONE, Inc. director Jeffrey W. Dunn reported a small, non-discretionary share sale tied to taxes. On May 4, 2026, a total of 337 shares of Common Stock were sold at a weighted average price of $13.1508 solely to cover tax withholding obligations from the vesting of restricted stock units under a “sell to cover” arrangement. Following this transaction, Dunn holds 9,157 shares directly, which include 8,675 shares issuable upon settlement of restricted stock units, and 80,591 shares indirectly through The Jeffrey W. Dunn Living Trust.
BlackRock, Inc. amended a Schedule 13G to report beneficial ownership of 3,057,039 shares of SI-BONE, Inc. common stock, representing 6.9% of the class. The filing shows sole voting power for 2,997,105 shares and sole dispositive power for 3,057,039 shares. The amendment is signed by Spencer Fleming, Managing Director on 04/24/2026.
SI-BONE, Inc. reported worldwide revenue of $200.9 million for fiscal 2025, representing an annual increase of approximately 20%. The company recorded a net loss of $18.9 million (an annual improvement of ~39%) and reported positive Adjusted EBITDA of $8.9 million. SI-BONE exited 2025 with $147.8 million in cash and equivalents and stated that more than 140,000 procedures have been performed worldwide since inception. The company highlighted commercial and regulatory progress, including launch of iFuse TORQ in Europe and a New Technology Add-on Payment (NTAP) for iFuse TORQ TNT effective October 1, 2025.
SI-BONE, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 4, 2026. Investors will elect two directors (Jeffrey W. Dunn and John G. Freund, M.D.) to terms ending in 2029, ratify PricewaterhouseCoopers LLP as auditor for 2026, and cast an advisory say-on-pay vote on executive compensation.
Management highlights 2025 results including worldwide revenue of $200.9 million, about 20% growth, a net loss of $18.9 million with roughly 39% improvement, positive Adjusted EBITDA of $8.9 million versus a prior loss, and year-end cash and equivalents of $147.8 million.
SI-BONE, Inc. director Greg K. Hinckley exercised stock options to acquire 3,085 shares of common stock at an exercise price of $5.94 per share. Following the transaction, he directly owns 105,135 shares of common stock.
This direct holding figure includes 8,675 shares issuable upon settlement of restricted stock units, each representing a right to receive one share of common stock. A portion of the shares is held with his spouse as community property with right of survivorship. The option exercised was part of a grant that vested in equal monthly installments over three years beginning on October 17, 2018.
SI-BONE, Inc. Chief Financial Officer Anshul Maheshwari reported selling 3,318 shares of common stock in two open-market transactions on April 2, 2026, at weighted average prices of $12.9228 and $12.8137 per share.
According to the footnotes, these sales were required to cover tax withholding obligations arising from the vesting of restricted stock units and were executed as "sell to cover" transactions, rather than discretionary trades. After these sales, Maheshwari directly owns 263,148 shares of SI-BONE common stock, including 193,458 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. senior vice president and chief legal officer Michael A. Pisetsky reported selling a total of 3,134 shares of common stock in open-market transactions on April 1–2, described as sales required to cover tax withholding on vesting restricted stock units under a “sell to cover” arrangement, rather than discretionary trades.
Sale prices ranged from about $12.55 to $13.09, with weighted averages around the reported prices. After these transactions, he holds 282,840 shares directly, which the disclosure states includes 151,034 shares issuable upon settlement of restricted stock units.